June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
The effectiveness of the ILUVIEN® (0.2 µg per day of mg fluocinolone acetonide) implant in the treatment of non-infectious posterior uveitis – 12-month outcomes from UAE
Author Affiliations & Notes
  • Avinash Gurbaxani
    Moorfields Eye Hospital Dubai, Dubai, Dubai, United Arab Emirates
  • Igor Kozak
    Moorfields Eye Hospital Dubai, Dubai, Dubai, United Arab Emirates
  • Footnotes
    Commercial Relationships   Avinash Gurbaxani, Alimera (C); Igor Kozak, Alimera (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Avinash Gurbaxani, Igor Kozak; The effectiveness of the ILUVIEN® (0.2 µg per day of mg fluocinolone acetonide) implant in the treatment of non-infectious posterior uveitis – 12-month outcomes from UAE. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The objective of this study was to evaluate the effectiveness and safety of the ILUVIEN (0.2 µg per day of mg fluocinolone acetonide [FAc]) implant (Alimera Sciences Inc., Georgia, USA) for the treatment of non-infectious posterior uveitis and to focus on the 12-month outcomes in seven patients (10 eyes) in clincial practice in the United Arab Emirates..

Methods : This prospective interventional case review surveyed consecutive patients. Ten eyes from seven patients were treated with the FAc implant for posterior uveitis at the Moorfields Eye Hospital in Abu Dhabi and Dubai, UAE between December 2018 and October 2020 . Patients were monitored for between 3 and 12 months (median, 9.0 months; 25th and 75th quartiles, 6.0 and 12.0) with best-corrected visual acuity (BCVA), central retinal thickness (CRT), vitritis and anterior chamber (AC) cell scores and intraocular pressure (IOP) being recorded.

Results : Diagnoses included panuveitis, retinal vasculitis , vitritis, pseudophakic CME / panuveitis, multifocal choroiditis, vasculitis. Prior treatment with a dexamethasone implant was doen in 5 of the 10 eyes (median, 2.0 implants; 25th and 75th quartiles, 1.0 and 2.0 implants). No systemic steroids were being given at the time of FAc therapy or during the 12 months of follow-up. At Month 12, BCVA increased by 16.1±5.5 ETDRS letters (mean±SD) from a baseline of 64.5±15.8 letters (P=0.0029); CRT improved by 79.0±96.0 microns from a baseline of 370.4±101.1 microns (P>0.05); and, mean IOP was unchanged from baseline (P>0.05), remaining below a mean value of 21 mmHg at all time points upto the 12 months. Baseline vitritis score was 1.4±1.2 and improved at months 3 (-0.8±0.8), 6 (-1.0±1.0) and 12 (-2.0±0.7). At Month 12, a vitritis score of zero was observed in four of the five treated eyes. A similar response was also seen for AC cells with the mean baseline value (0.5±0.8) improving at months 3 (-0.4±0.8), 6 (-0.6±0.9) and 12 (-1.0±1.0). Adverse events included posterior capsule opacification in one eye which was managed with YAG laser. Another eye had an epiretinal membrane, but this was not related to treatment.

Conclusions : Results gained from treating patients in clinical practice in the UAE show the FA implant to be effective in the treatment of non-infectious posterior uveitis affecting the posterior segment of the eye.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×